2024-07-24 09:25:00
The goal is to detect the genes responsible for breaking down tuberculosis in patients, so that treating physicians have information to adjust medications suitable for each patient. This will help reduce the occurrence of liver inflammation from anti-tuberculosis drugs, allowing for continuous medication intake, which is crucial for achieving the goal of ending tuberculosis.
Additionally, Mr. Somsak stated in an interview with the media that he would like to thank the Department of Medical Sciences for introducing a new innovation, the Nat2 Dypotyping test, which will help determine how each individual’s Nat2 Dypotyping can metabolize tuberculosis medications. If some individuals’ Nat2 Dypotyping works well, the tuberculosis medication will be broken down quickly, leading to less effective treatment. Conversely, if some individuals’ Nat2 Dypotyping does not function well, the tuberculosis medication will remain in the system, resulting in liver inflammation.
Therefore, the Nat2 Dypotyping test will enable physicians to prescribe medications more appropriately. This is necessary because each year there are 80,000 cases of tuberculosis and 7,800 deaths. If we have the Nat2 Dypotyping test, it will help reduce mortality.
When asked whether the Nat2 Dypotyping test is not yet included in the benefits for the public, Mr. Somsak said that it is not yet part of the benefits but he will push for it in the National Health Security Office (NHSO) because it is beneficial for the public and the examination cost is not high, with only a few hundred baht.
Revolutionizing Tuberculosis Treatment: The Future of Gene Testing
Recent advancements in tuberculosis (TB) treatment are paving the way for more personalized healthcare strategies, especially in the realm of gene testing. The introduction of a new gene assay capable of detecting TB genes in patients promises to enhance clinical decision-making by providing invaluable insights to healthcare professionals. This innovation aims to tailor drug regimens to individual patient responses, significantly reducing the risk of drug-induced liver injuries and ensuring consistent medication adherence, which is crucial to achieving the global goal of eradicating tuberculosis.
The innovation, known as the “NAT2 Dihydrotestosterone Test,” is designed to identify how effectively patients can metabolize TB medication. This is critical information, as it addresses the variability in drug metabolism among individuals. For some, a well-functioning NAT2 pathway means quicker drug breakdown, which could lead to suboptimal treatment outcomes. Conversely, those with less effective NAT2 pathways may experience prolonged drug action, increasing the risk of liver damage due to drug accumulation.
This targeted approach holds promise for reducing the staggering statistics associated with tuberculosis in regions where it remains highly prevalent. With approximately 80,000 new TB cases reported annually and 7,800 fatalities, optimizing treatment using gene testing could lead to significant reductions in mortality rates. The adoption of NAT2 testing could represent a vital step in addressing public health challenges by enhancing drug efficacy and patient safety.
While this gene testing is currently not included in public health coverage, there are discussions underway to advocate for its integration into national health benefit schemes. With testing costs estimated to be relatively low—within the range of a few hundred baht—the potential for widespread access is on the horizon. This could democratize advanced TB treatment, making it accessible to a wider population, ultimately leading towards healthier communities and a decrease in TB-related deaths.